`FOR THE WESTERN DISTRICT OF PENNSYLVANIA
`
`BAUSCH HEALTH IRELAND LIMITED,
`and SALIX PHARMACEUTICALS, INC.,
`
`Plaintiffs,
`
`v.
`
`MYLAN LABORATORIES LTD.,
`AGILA SPECIALTIES INC., MYLAN
`API US LLC, MYLAN INC.,
`VIATRIS INC., and MYLAN
`PHARMACEUTICALS INC. -
`A VIATRIS COMPANY,
`
`
`Defendants.
`
`)
`)
`)
`)
`)
`)
`)
`) Civil Action No. 21-573
`)
`)
`)
`)
`)
`)
`)
`
`ORDER OF COURT
`
`AND NOW, this 6th day of April, 2022, upon consideration of Defendants’ Unopposed
`
`Motion to Stay (Docket No. 68) filed by Defendants Mylan Laboratories Ltd., Agila Specialties
`
`Inc., Mylan API US LLC, MYLAN Inc., Viatris Inc., and Mylan Pharmaceuticals Inc, and based
`
`on the fact that Plaintiffs’ first-filed, substantively similar action is now proceeding in the Northern
`
`District of West Virginia, IT IS ORDERED that said motion is GRANTED. This matter shall be
`
`stayed and administratively closed until the disposition of Bausch Health Ireland Ltd., et al. v.
`
`Mylan Labs. Ltd., et al., No. 1:22-cv-00020-TSK, in the Northern District of West Virginia,
`
`including any potential appeal. The parties shall notify this Court within 30 days of the disposition
`
`of the above mentioned case.
`
`IT IS FURTHER ORDERED that Defendant’s Motion to Dismiss (Docket No. 25) and
`
`Plaintiffs’ Cross-Motion for Venue/Jurisdictional Discovery (Docket No. 45) are DENIED
`
`without prejudice to refiling, and Plaintiffs’ Motion to Stay the Second-Filed Case in the Western
`
`1
`
`MYLAN - EXHIBIT 1035
`
`
`
`District of Pennsylvania (Docket No. 47) is DENIED AS MOOT.
`
` s/ W. Scott Hardy
` W. Scott Hardy
` United States District Judge
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`cc/ecf: All counsel of record
`
`
`
`
`
`
`2
`
`
`